Tag Archives: The Stem Cell Blog

WideCells establishes ‘end-to-end’ stem cell service – Proactive Investors UK

Continue reading

2018-04-12 NEWS

Proactive Investors UK

WideCells establishes ‘end-to-end’ stem cell service
Proactive Investors UK
CellPlan is a stem cell healthcare insurance plan that makes stem cell transplants affordable for families who require treatment for life-threatening diseases. WideCells Group Science focuses on stem cell research and stem cell storage. Wideacademy …

Continue reading

2018-04-12 NEWS

Business Wire (press release)

Pfizer Doses First Patient Using Investigational Mini-Dystrophin …
Business Wire (press release)
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene …
Pfizer Begins Clinical Trial With Mini-dystrophin Gene Therapy CandidateNasdaq
Pfizer (PFE) Commences Phase 1b Clinical Trial for Investigational …StreetInsider.com
First Duchenne Patient Dosed in Pfizer’s Mini-Dystrophin StudyRare Disease Report

all 1 news articles »

Continue reading

2018-04-12 NEWS

Immuno-Oncology News

Society of Interventional Oncology and BTG Award Five Cancer Research Grants
Immuno-Oncology News
The Society of Interventional Oncology (SIO) and the therapy development company BTG have chosen five winners of this year’s Immuno-Oncology/Interventional Oncology research grants. They founded the program in 2017 to fund cutting-edge immunotherapy …

Continue reading

2018-04-12 NEWS

Xconomy

As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal
Xconomy
Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market but has struggled to sell it, is …
GSK sells rare disease gene therapy portfolio – Financial TimesFinancial Times
GSK slims portfolio with sale of rare disease gene therapy drugsReuters
UK gene therapy firm Orchard plans stock offer after GSK dealWHTC
GlobeNewswire (press release) –Genetic Engineering & Biotechnology News –Zacks
all 110 news articles »